Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2025-02-12 00:00:00 ET · period of report 2025-02-11 · accession 0001415889-25-003822 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-02-12 | 2025-02-11 | TVTX | Calvin Sandra | SVP, CAO | M - OptEx | $16.63 | +45.0K | 73.7K | +157% | +$748.2K |
| DM | 2025-02-12 | 2025-02-11 | TVTX | Calvin Sandra | SVP, CAO | S - Sale+OE | $25.00 | -54.2K | 63.7K | -46% | -$1.36M |
| DM | 2025-02-12 | 2025-02-11 | TVTX | Calvin Sandra | SVP, CAO | M - OptEx | $0.00 | -45.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-11 | M | A | 10,000 | $16.23 | 73,654 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-11 | S | D | 10,000 | $25.00 | 63,654 | D | — | — | |
| 3 | Common | Common Stock | 2025-02-11 | M | A | 10,000 | $17.44 | 73,654 | D | — | — | |
| 4 | Common | Common Stock | 2025-02-11 | S | D | 10,000 | $25.00 | 63,654 | D | — | — | |
| 5 | Common | Common Stock | 2025-02-11 | S | D | 9,244 | $25.00 | 54,410 | D | — | — | |
| 6 | Common | Common Stock | 2025-02-11 | S | D | 10,000 | $25.00 | 63,654 | D | — | — | |
| 7 | Common | Common Stock | 2025-02-11 | M | A | 15,000 | $15.46 | 78,654 | D | — | — | |
| 8 | Common | Common Stock | 2025-02-11 | S | D | 15,000 | $25.00 | 63,654 | D | — | — | |
| 9 | Common | Common Stock | 2025-02-11 | M | A | 10,000 | $17.96 | 73,654 | D | — | — | |
| 10 | Derivative | Employee stock option (right to buy) | 2025-02-11 | M | D | 10,000 | $0.00 | 0 | D | $17.96 · — to 2029-05-09 | 10,000 Common Stock | (F6) The stock option is fully vested and exercisable. |
| 11 | Derivative | Employee stock option (right to buy) | 2025-02-11 | M | D | 10,000 | $0.00 | 0 | D | $17.44 · — to 2027-05-17 | 10,000 Common Stock | (F6) The stock option is fully vested and exercisable. |
| 12 | Derivative | Employee stock option (right to buy) | 2025-02-11 | M | D | 15,000 | $0.00 | 0 | D | $15.46 · — to 2030-01-31 | 15,000 Common Stock | (F6) The stock option is fully vested and exercisable. |
| 13 | Derivative | Employee stock option (right to buy) | 2025-02-11 | M | D | 10,000 | $0.00 | 0 | D | $16.23 · — to 2026-05-19 | 10,000 Common Stock | (F6) The stock option is fully vested and exercisable. |